Literature DB >> 3007962

Vasopressin receptor-adenylate cyclase interactions. Studies in an intact cultured renal epithelial cell line (LLC-PK1).

K L Skorecki, A S Verkman, D A Ausiello.   

Abstract

The antidiuretic action of vasopressin is mediated by activation of adenylate cyclase and generation of cyclic AMP. Radioligand binding and radiation inactivation studies have been done using a pig kidney epithelial cell line in culture to define the sequence of subunit interactions involved in the activation of adenylate cyclase by vasopressin. Based on the results of these studies and the known biochemical properties of the individual adenylate cyclase subunits, a hormonal activation model is proposed. According to this model, activation results from the sequential steps of dissociation of the alpha beta subunits of the guanyl nucleotide regulatory unit followed by the binding of GTP to dissociated alpha. The development of this model would not have been possible without the availability of the intact cultured cell system.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3007962

Source DB:  PubMed          Journal:  Miner Electrolyte Metab        ISSN: 0378-0392


  3 in total

1.  Proximal tubular epithelial cells possess a novel 42-kilodalton guanine nucleotide-binding regulatory protein.

Authors:  J Zhou; C Sims; C H Chang; L Berti-Mattera; U Hopfer; J Douglas
Journal:  Proc Natl Acad Sci U S A       Date:  1990-10       Impact factor: 11.205

2.  Lateral mobility of the phospholipase C-activating vasopressin V1-type receptor in A7r5 smooth muscle cells: a comparison with the adenylate cyclase-coupled V2-receptor.

Authors:  D A Jans; R Peters; F Fahrenholz
Journal:  EMBO J       Date:  1990-09       Impact factor: 11.598

3.  The adenylate cyclase-coupled vasopressin V2-receptor is highly laterally mobile in membranes of LLC-PK1 renal epithelial cells at physiological temperature.

Authors:  D A Jans; R Peters; J Zsigo; F Fahrenholz
Journal:  EMBO J       Date:  1989-09       Impact factor: 11.598

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.